Xencor, Inc. (XNCR)
Largest Insider Buys in Sector
XNCR Stock Price History Chart
XNCR Stock Performance
About Xencor, Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted …
Insider Activity of Xencor, Inc.
Over the last 12 months, insiders at Xencor, Inc. have bought $1,013 and sold $5.87M worth of Xencor, Inc. stock.
On average, over the past 5 years, insiders at Xencor, Inc. have bought $1,013 and sold $11.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GORMAN KEVIN CHARLES (director) — $2,027.
The last purchase of 53 shares for transaction amount of $1,013 was made by GORMAN KEVIN CHARLES (director) on 2024‑02‑13.
List of Insider Buy and Sell Transactions, Xencor, Inc.
| 2024-11-13 | Sale | PRESIDENT & CEO | 3,366 0.0049% | $24.02 | $80,842 | +0.47% | ||
| 2024-11-11 | Sale | SR. VICE PRESIDENT & CSO | 68,684 0.0989% | $23.48 | $1.61M | +1.72% | ||
| 2024-09-27 | Sale | director | 2,503 0.0036% | $20.68 | $51,762 | +5.06% | ||
| 2024-09-27 | Sale | director | 1,853 0.0027% | $20.68 | $38,320 | +5.06% | ||
| 2024-09-27 | Sale | director | 2,503 0.0036% | $20.68 | $51,762 | +5.06% | ||
| 2024-09-27 | Sale | director | 2,503 0.0036% | $20.68 | $51,762 | +5.06% | ||
| 2024-09-27 | Sale | director | 2,503 0.0036% | $20.68 | $51,762 | +5.06% | ||
| 2024-09-27 | Sale | director | 2,654 0.0038% | $20.68 | $54,885 | +5.06% | ||
| 2024-07-09 | Sale | SR. VICE PRESIDENT & CSO | 36,329 0.0555% | $18.32 | $665,511 | 0.00% | ||
| 2024-05-02 | Sale | EVP, Chief Development Officer | 4,745 0.0077% | $23.58 | $111,872 | -10.95% | ||
| 2024-03-11 | Sale | PRESIDENT & CEO | 2,741 0.0046% | $23.50 | $64,418 | -8.98% | ||
| 2024-03-11 | Sale | SR. VICE PRESIDENT & CSO | 1,280 0.0021% | $23.50 | $30,082 | -8.98% | ||
| 2024-03-11 | Sale | SR. VICE PRESIDENT & CFO | 849 0.0014% | $23.50 | $19,953 | -8.98% | ||
| 2024-03-11 | Sale | SVP, GENERAL COUNSEL | 850 0.0014% | $23.50 | $19,977 | -8.98% | ||
| 2024-03-06 | Sale | director | 14,000 0.0222% | $23.18 | $324,453 | -11.25% | ||
| 2024-03-05 | Sale | PRESIDENT & CEO | 12,528 0.0209% | $23.43 | $293,519 | -7.44% | ||
| 2024-03-05 | Sale | SR. VICE PRESIDENT & CSO | 6,629 0.011% | $23.43 | $155,311 | -7.44% | ||
| 2024-03-05 | Sale | SR. VICE PRESIDENT & CFO | 4,474 0.0075% | $23.43 | $104,821 | -7.44% | ||
| 2024-03-05 | Sale | SVP, GENERAL COUNSEL | 3,892 0.0065% | $23.43 | $91,186 | -7.44% | ||
| 2024-02-13 | Sale | SR. VICE PRESIDENT & CSO | 54,108 0.084% | $19.38 | $1.05M | +11.40% |
Insider Historical Profitability
| GORMAN KEVIN CHARLES | director | 8392 0.012% | $24.92 | 1 | 1 | |
| STAFFORD JOHN S JR | 10 percent owner | 2000443 2.8585% | $24.92 | 1 | 0 | +31.06% |
| STAFFORD JOHN S III | 10 percent owner | 606005 0.8659% | $24.92 | 33 | 42 | +42.66% |
Institutional Investor Ownership
| BlackRock | $244.64M | 17.93 | 11.05M | -2.37% | -$5.95M | 0.01 | |
| PRIMECAP Management Co | $201.18M | 14.74 | 9.09M | +2.12% | +$4.18M | 0.15 | |
| The Vanguard Group | $155.15M | 11.37 | 7.01M | +3.6% | +$5.4M | <0.01 | |
| Ecor1 Capital Llc | $117.96M | 8.64 | 5.33M | +0.91% | +$1.06M | 0.83 | |
| State Street | $93.73M | 6.87 | 4.24M | +27.31% | +$20.11M | <0.01 |